Received Feb 17, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (NO BRAND NAME) | UNKNOWN MANUFACTURER | 1 | UNK | — |
fever; Headache; was in bed; This non-serious case was reported by a consumer via interactive digital media and described the occurrence of fever in a patient who received Herpes zoster (Shingles vaccine) for prophylaxis. On an unknown date, the patient received the 1st dose of Shingles vaccine. On an unknown date, an unknown time after receiving Shingles vaccine, the patient experienced fever (Verbatim: fever), headache (Verbatim: Headache) and bedridden (Verbatim: was in bed). The outcome of the fever, headache and bedridden were not reported. It was unknown if the reporter considered the fever, headache and bedridden to be related to Shingles vaccine. It was unknown if the company considered the fever, headache and bedridden to be related to Shingles vaccine. Linked case(s) involving the same patient:US2026AMR020633 Additional Information: GSK Receipt Date: 07-FEB-2026 This case was reported by a patient via interactive digital media. The batch number was not provided, and we are unable to contact the reporter. For tolerance of 2nd dose of Shingles vaccine, refer case US2026AMR020633.; Sender's Comments: US-GSK-US2026AMR020633:SAME PATIENT